Biocryst Pharmaceuticals Inc (BCRX) Revenue (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Revenue for 17 consecutive years, with $156.4 million the latest figure, recorded in Q1 2026.

• Revenue for Q1 2026 came in at $156.4 million, up 7.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $479.9 million (down 4.69% YoY), and the FY2025 annual result was $874.8 million, up 94.1% from the prior year.
• Revenue was $156.4 million for Q1 2026 at Biocryst Pharmaceuticals, up from $708000.0 in the prior quarter.
• Over five years, Revenue peaked at $163.4 million in Q2 2025 and troughed at $708000.0 in Q4 2025.
• Average Revenue over 5 years is $98.7 million, with a median of $92.8 million recorded in 2024.
• Year-over-year, Revenue jumped 161.94% in 2022 and tumbled 99.46% in 2025.
• Over 5 years, Revenue stood at $79.5 million in 2022, then gained by 17.42% to $93.4 million in 2023, then jumped by 40.83% to $131.5 million in 2024, then sank by 99.46% to $708000.0 in 2025, then surged by 21992.23% to $156.4 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $156.4 million in Q1 2026, $708000.0 in Q4 2025, and $159.4 million in Q3 2025.